Literature DB >> 18022208

Inhibition of cellular entry of lymphocytic choriomeningitis virus by amphipathic DNA polymers.

Andrew M Lee1, Jillian M Rojek, Anette Gundersen, Ute Ströher, Jean-Marc Juteau, Andrew Vaillant, Stefan Kunz.   

Abstract

The prototypic arenavirus lymphocytic choriomeningitis virus (LCMV) represents a powerful experimental model for the study of the basic virology and pathogenesis of arenaviruses. In the present study, we used the LCMV model to evaluate the anti-viral potential of phosphorothioate oligonucleotides against arenaviruses. Our findings indicate that amphipathic DNA polymers (APs) are potent inhibitors of infection with a series of LCMV isolates with IC(50) in the low nanomolar range. APs target the surface glycoprotein (GP) of LCMV and block viral entry and cell-cell propagation of the virus, without affecting later steps in replication or release of progeny virus from infected cells. The anti-viral action of APs is sequence-independent but is critically dependent on their size and hydrophobicity. Mechanistically, we provide evidence that APs disrupt the interaction between LCMVGP and its cellular receptor, alpha-dystroglycan. Exposure of LCMV to APs does not affect the stability of the GP virion spike and has no effect on the conformation of a neutralizing antibody epitope, suggesting rather subtle changes in the conformation and/or conformational dynamics of the viral GP.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 18022208      PMCID: PMC2821746          DOI: 10.1016/j.virol.2007.10.016

Source DB:  PubMed          Journal:  Virology        ISSN: 0042-6822            Impact factor:   3.616


  48 in total

Review 1.  Biology and pathogenesis of lymphocytic choriomeningitis virus infection.

Authors:  M B A Oldstone
Journal:  Curr Top Microbiol Immunol       Date:  2002       Impact factor: 4.291

2.  Lassa fever in the Eastern Province of Sierra Leone, 1970-1972. II. Clinical observations and virological studies on selected hospital cases.

Authors:  T P Monath; M Maher; J Casals; R E Kissling; A Cacciapuoti
Journal:  Am J Trop Med Hyg       Date:  1974-11       Impact factor: 2.345

3.  Monoclonal antibodies to lymphocytic choriomeningitis and pichinde viruses: generation, characterization, and cross-reactivity with other arenaviruses.

Authors:  M J Buchmeier; H A Lewicki; O Tomori; M B Oldstone
Journal:  Virology       Date:  1981-08       Impact factor: 3.616

4.  Protection of Lassa virus-infected guinea pigs with Lassa-immune plasma of guinea pig, primate, and human origin.

Authors:  P B Jahrling
Journal:  J Med Virol       Date:  1983       Impact factor: 2.327

5.  Genomic and biological variation among commonly used lymphocytic choriomeningitis virus strains.

Authors:  F J Dutko; M B Oldstone
Journal:  J Gen Virol       Date:  1983-08       Impact factor: 3.891

6.  Passive antibody therapy of Lassa fever in cynomolgus monkeys: importance of neutralizing antibody and Lassa virus strain.

Authors:  P B Jahrling; C J Peters
Journal:  Infect Immun       Date:  1984-05       Impact factor: 3.441

7.  Enhanced treatment of Lassa fever by immune plasma combined with ribavirin in cynomolgus monkeys.

Authors:  P B Jahrling; C J Peters; E L Stephen
Journal:  J Infect Dis       Date:  1984-03       Impact factor: 5.226

8.  Lassa fever, a new virus disease of man from West Africa. II. Report of a laboratory-acquired infection treated with plasma from a person recently recovered from the disease.

Authors:  E Leifer; D J Gocke; H Bourne
Journal:  Am J Trop Med Hyg       Date:  1970-07       Impact factor: 2.345

9.  Old World and clade C New World arenaviruses mimic the molecular mechanism of receptor recognition used by alpha-dystroglycan's host-derived ligands.

Authors:  Jillian M Rojek; Christina F Spiropoulou; Kevin P Campbell; Stefan Kunz
Journal:  J Virol       Date:  2007-03-14       Impact factor: 5.103

10.  The viral transmembrane superfamily: possible divergence of Arenavirus and Filovirus glycoproteins from a common RNA virus ancestor.

Authors:  W R Gallaher; C DiSimone; M J Buchmeier
Journal:  BMC Microbiol       Date:  2001-02-09       Impact factor: 3.605

View more
  27 in total

Review 1.  Novel approaches in anti-arenaviral drug development.

Authors:  Andrew M Lee; Antonella Pasquato; Stefan Kunz
Journal:  Virology       Date:  2010-12-22       Impact factor: 3.616

2.  Gumming up the works: DNA polymers as HCV entry inhibitors.

Authors:  Natalie A Counihan; Brett D Lindenbach
Journal:  Gastroenterology       Date:  2009-06-27       Impact factor: 22.682

3.  Ribavirin can be mutagenic for arenaviruses.

Authors:  Héctor Moreno; Isabel Gallego; Noemí Sevilla; Juan Carlos de la Torre; Esteban Domingo; Verónica Martín
Journal:  J Virol       Date:  2011-05-11       Impact factor: 5.103

Review 4.  Progress in the experimental therapy of severe arenaviral infections.

Authors:  Brian B Gowen; Mike Bray
Journal:  Future Microbiol       Date:  2011-12       Impact factor: 3.165

Review 5.  Lymphocytic choriomeningitis virus (LCMV) infection of macaques: a model for Lassa fever.

Authors:  Juan C Zapata; C David Pauza; Mahmoud M Djavani; Juan D Rodas; Dmitry Moshkoff; Joseph Bryant; Eugene Ateh; Cybele Garcia; Igor S Lukashevich; Maria S Salvato
Journal:  Antiviral Res       Date:  2011-07-27       Impact factor: 5.970

6.  Nucleic Acid Polymers Are Active against Hepatitis Delta Virus Infection In Vitro.

Authors:  Frauke Beilstein; Matthieu Blanchet; Andrew Vaillant; Camille Sureau
Journal:  J Virol       Date:  2018-01-30       Impact factor: 5.103

7.  Oligonucleotides designed to inhibit TLR9 block Herpes simplex virus type 1 infection at multiple steps.

Authors:  Monica M Sauter; Joshua J L Gauger; Curtis R Brandt
Journal:  Antiviral Res       Date:  2014-07-01       Impact factor: 5.970

8.  Amphipathic DNA polymers inhibit hepatitis C virus infection by blocking viral entry.

Authors:  Takuya Matsumura; Zongyi Hu; Takanobu Kato; Marlene Dreux; Yong-Yuan Zhang; Michio Imamura; Nobuhiko Hiraga; Jean-Marc Juteau; Francois-Loic Cosset; Kazuaki Chayama; Andrew Vaillant; T Jake Liang
Journal:  Gastroenterology       Date:  2009-04-23       Impact factor: 22.682

9.  Targeting the proteolytic processing of the viral glycoprotein precursor is a promising novel antiviral strategy against arenaviruses.

Authors:  Jillian M Rojek; Giulia Pasqual; Ana B Sanchez; Ngoc-Thao Nguyen; Juan-Carlos de la Torre; Stefan Kunz
Journal:  J Virol       Date:  2010-01       Impact factor: 5.103

10.  Amphipathic DNA polymers exhibit antiviral activity against systemic murine Cytomegalovirus infection.

Authors:  Rhonda D Cardin; Fernando J Bravo; Andrea P Sewell; James Cummins; Louis Flamand; Jean-Marc Juteau; David I Bernstein; Andrew Vaillant
Journal:  Virol J       Date:  2009-12-02       Impact factor: 4.099

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.